Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Standard Biotools (LAB) Current Taxes (2022 - 2026)

Standard Biotools has reported Current Taxes over the past 2 years, most recently at $1.2 million for Q4 2023.

Quarterly Current Taxes fell 14.76% to $1.2 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2023, down 14.76% year-over-year, with the annual reading at $1.2 million for FY2023, 14.76% down from the prior year.
Current Taxes was $1.2 million for Q4 2023 at Standard Biotools, up from $1.1 million in the prior quarter.
Over five years, Current Taxes peaked at $1.4 million in Q4 2022 and troughed at $1.1 million in Q3 2023.